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EDITORIALA Twist in the Tale of a Pig Model of Short-Bowel Syndromehort-bowel syndrome (SBS) occurs after a long sur-Sgical resection of small intestine. This results in
malabsorption of nutrients, especially lipids, and is associ-
ated with the development of liver disease. It is particularly
serious in infants. The contributions of altered lipid meta-
bolism, bile acid physiology, dysbiosis, and supplemental
enteral or parenteral nutrition to the development of this
pathology remain unclear, and a piglet model has provided
useful evidence due to various similarities with humans.1
In the study of SBS-induced liver damage by Pereira-
Fantini et al2 published in this issue of Cellular and Molec-
ular Gastroenterology and Hepatology, piglets had resection
of 75% of the small intestine, leaving duodenum and
terminal ileum in situ, or a sham operation. Animals were
fed with oral formula and were studied 2 weeks postsurgery
when liver, terminal ileum, bile, and portal blood samples
were collected. Half the piglets in each group were given the
farnesoid X receptor (FXR) agonist, obeticholic acid
(OCA). This is a semisynthetic bile acid, with an additional
6-alpha-ethyl group, which increases its potency at the FXR,
in mouse and humans at least, by almost 100-fold. OCA has
been shown to be beneﬁcial in many animal models of
cholestasis and steatosis, and in clinical trials for primary
biliary cholangitis, nonalcoholic steatohepatitis, and primary
bile acid diarrhea.3–5 OCA was a plausible drug to study as
previous work by the same authors had suggested impaired
FXR responses in SBS piglets.6 Also, in the parenteral
nutrition–fed piglet, the most potent natural bile acid FXR
agonist, chenodeoxycholic acid, improved the liver disease.7
As expected, in the SBS model weight gain was reduced,
feces were unformed and fatty (steatorrhea), and liver
changes including lipid droplets and clusters of inﬂamma-
tory cells were found. OCA treatment reduced stool fat to a
large extent, improving absorption. SBS was associated with
depletion of biliary taurine and OCA reversed this. There
were many changes in the composition of bile acids in the
bile in SBS, in particular a large increase in hyocholic acid,
which is a major primary bile acid in the pig. There were
major decreases in SBS of the secondary bile acids, which
result from intestinal bacterial metabolism. OCA treatment
partially restored these conjugated secondary bile acids in
bile.
The rate-limiting gene for bile acid synthesis by the
classical pathway in the liver is CYP7A1, and expression of
this was potently inhibited by OCA in control and SBS pigs,
as reported in other species. OCA up-regulated several other
known FXR-responsive genes in the liver and there were
only minor differences between its effects in control or SBS
animals.
However, there were several unexpected ﬁndings. In the
SBS animals, OCA resulted in more fat accumulation in the
liver and a signiﬁcant reduction in lobule size. Intestinal FXRCellutarget gene expression was surprisingly reduced by
OCA—and importantly this was seen in the control group as
well as in the SBS group. In the human ileum, FXR agonists
such as chenodeoxycholic acid or OCA stimulate expression
of speciﬁc genes involved in bile acid reabsorption. Partic-
ularly, the ileum-derived hormone, ﬁbroblast growth factor
19, is up-regulated by FXR agonists8 and acts in the liver as
the major inhibitor of CYP7A1.9 In the pig, ﬁbroblast growth
factor 19 transcripts were also signiﬁcantly down-regulated
by OCA. Expression of FXR itself was increased in SBS in
both the liver and the intestine, with OCA stimulating FXR in
the control liver but inhibiting FXR in the SBS intestine.
How should we interpret these ﬁndings? Probably most
importantly, pigs are not human. Hyocholic acid is 1 of the 2
major primary bile acids in pigs, unlike in humans. The
effects of hyocholic acid, and the derived hyodeoxycholic
acid, at the FXR, as agonists or antagonists, are unknown.
Hyocholic acid is a 6-hydroxylated bile acid, in the alpha
position. In the mouse, muricholic acid is 6-beta hydroxyl-
ated and is a poor FXR agonist, whereas OCA has an ethyl
group in the 6-alpha position and is very potent. There are
also different spliced variants of FXR, with different effects
in pigs and humans.10 The gut microbiome is critical for
production of secondary bile acids and also differs.
Overall, interpretation of the relevance of these ﬁndings
to human physiology and SBS therapeutics is unclear.
Further studies are required to understand these effects in
pigs and how these differences affect bile acid and FXR
functions. This work has shown clearly the complexities of
the bile acid-FXR system in the liver and intestine and will
stimulate discussion as to how this can best be targeted for
therapy.
JULIAN R. F. WALTERS, MA, MB, FRCP
Division of Digestive Diseases
Imperial College London & Imperial
College Healthcare NHS Trust
London, United Kingdom
References
1. Lim DW, Turner JM, Wales PW. Emerging piglet models
of neonatal short bowel syndrome. JPEN J Parenter
Enteral Nutr 2015;39:636–643.
2. Pereira-Fantini PM, Lapthorne S, Gahan CGM, Joyce SA,
Charles J, Fuller PJ, Bines JE. Farnesoid X receptor
agonist treatment alters bile acid metabolism but exac-
erbates liver damage in a piglet model of short-bowel
syndrome. Cell Mol Gastroenterol Hepatol 2017;4:65–74.
3. Nevens F, Andreone P, Mazzella G, Strasser SI,
Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J,
Beuers U, Trauner M, Jones DE, Floreani A,
Hohenester S, Luketic V, Shiffman M, van Erpecum KJ,lar and Molecular Gastroenterology and Hepatology 2017;4:201–202
202 Julian R. F. Walters Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 1Vargas V, Vincent C, Hirschﬁeld GM, Shah H, Hansen B,
Lindor KD, Marschall HU, Kowdley KV, Hooshmand-
Rad R, Marmon T, Sheeron S, Pencek R, MacConell L,
Pruzanski M, Shapiro D. A placebo-controlled trial of
obeticholic acid in primary biliary cholangitis. N Engl J
Med 2016;375:631–643.
4. Neuschwander-Tetri BA, Loomba R, Sanyal AJ,
Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N,
Dasarathy S, Diehl AM, Hameed B, Kowdley KV,
McCullough A, Terrault N, Clark JM, Tonascia J,
Brunt EM, Kleiner DE, Doo E. Farnesoid X nuclear
receptor ligand obeticholic acid for non-cirrhotic,
non-alcoholic steatohepatitis (FLINT): a multicentre,
randomised, placebo-controlled trial. Lancet 2015;385:
956–965.
5. Walters JR, Johnston IM, Nolan JD, Vassie C,
Pruzanski ME, Shapiro DA. The response of patients with
bile acid diarrhoea to the farnesoid X receptor agonist
obeticholic acid. Aliment Pharmacol Ther 2015;41:54–64.
6. Pereira-Fantini PM, Lapthorne S, Joyce SA, Dellios NL,
Wilson G, Fouhy F, Thomas SL, Scurr M, Hill C,
Gahan CG, Cotter PD, Fuller PJ, Hardikar W, Bines JE.
Altered FXR signalling is associated with bile acid dys-
metabolism in short bowel syndrome-associated liver
disease. J Hepatol 2014;61:1115–1125.
7. Jain AK, Stoll B, Burrin DG, Holst JJ, Moore DD. Enteral
bile acid treatment improves parenteral nutrition-relatedliver disease and intestinal mucosal atrophy in neonatal
pigs. Am J Physiol Gastrointest Liver Physiol 2012;
302:G218–G224.
8. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T,
Dixon PH, Williamson C, Walters JR. Potent stimulation
of ﬁbroblast growth factor 19 expression in the human
ileum by bile acids. Am J Physiol Gastrointest Liver
Physiol 2013;304:G940–G948.
9. Keely SJ, Walters JR. The Farnesoid X receptor: good for
BAD. Cell Mol Gastroenterol Hepatol 2016;2:725–732.
10. Gray MA, James SE. Investigation of the dominant pos-
itive effect of porcine farnesoid X receptor (FXR) splice
variant 1. Gene 2015;560:71–76.Correspondence
Address correspondence to: Julian Walters, MA, MB, FRCP, Department of
Gastroenterology, Hammersmith Hospital, Du Cane Road, London W12 0HS,
United Kingdom. e-mail: julian.walters@imperial.ac.uk.
Conﬂicts of interest
JRFW has served as a speaker, advisory board member, or consultant for
Albireo, GE Healthcare, Intercept Pharmaceuticals, NGM Biopharmaceuticals,
and Novartis.
Most current article
© 2017 The Author. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2017.04.003
